Following these proceedings, Evercore ISI downgraded its Cabaletta Bio Inc [CABA] rating to an In-line from a an Outperform in a research note published on December 20, 2024; the price target was decreased to $6 from $15. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in mid December from “an Overweight” to “an Equal weight”. UBS began covering CABA with “Buy” recommendation on October 10, 2024. Jefferies started covering the stock on February 05, 2024. It rated CABA as “a Buy”.
Price Performance Review of CABA
On Friday, Cabaletta Bio Inc [NASDAQ:CABA] saw its stock jump 12.76% to $2.74. Over the last five days, the stock has gained 32.05%. Cabaletta Bio Inc shares have risen nearly 20.70% since the year began. Nevertheless, the stocks have fallen -86.76% over the past one year. While a 52-week high of $26.35 was reached on 01/07/25, a 52-week low of $1.76 was recorded on 01/13/25. SMA at 50 days reached $2.91, while 200 days put it at $6.80.
Levels Of Support And Resistance For CABA Stock
The 24-hour chart illustrates a support level at 2.46, which if violated will result in even more drops to 2.19. On the upside, there is a resistance level at 2.93. A further resistance level may holdings at 3.13. The Relative Strength Index (RSI) on the 14-day chart is 54.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.11, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 14.81%. Stochastics %K at 55.70% indicates the stock is a holding.
How much short interest is there in Cabaletta Bio Inc?
A steep rise in short interest was recorded in Cabaletta Bio Inc stocks on 2024-10-31, dropping by -1.62 million shares to a total of 3.71 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 5.32 million shares. There was a decline of -43.65%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 29, 2023 when William Blair began covering the stock and recommended ‘”an Outperform”‘ rating along with a $38 price target.
